## Jacob J Mandel

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/438635/publications.pdf

Version: 2024-02-01

44 papers 843 citations

687363 13 h-index 28 g-index

44 all docs

44 docs citations

44 times ranked 1570 citing authors

#	Article	IF	CITATIONS
1	Factors Associated With Age Disparities Among Cancer Clinical Trial Participants. JAMA Oncology, 2019, 5, 1769.	7.1	161
2	Neurologic complications of immune checkpoint inhibitors. Journal of Neuro-Oncology, 2018, 137, 601-609.	2.9	126
3	Window-of-opportunity clinical trial of pembrolizumab in patients with recurrent glioblastoma reveals predominance of immune-suppressive macrophages. Neuro-Oncology, 2020, 22, 539-549.	1.2	98
4	Primary and secondary gliosarcomas: clinical, molecular and survival characteristics. Journal of Neuro-Oncology, 2015, 125, 401-410.	2.9	59
5	Inability of positive phase II clinical trials of investigational treatments to subsequently predict positive phase III clinical trials in glioblastoma. Neuro-Oncology, 2018, 20, 113-122.	1.2	56
6	Leptomeningeal dissemination in glioblastoma; an inspection of risk factors, treatment, and outcomes at a single institution. Journal of Neuro-Oncology, 2014, 120, 597-605.	2.9	50
7	Impact of IDH1 mutation status on outcome in clinical trials for recurrent glioblastoma. Journal of Neuro-Oncology, 2016, 129, 147-154.	2.9	36
8	Paraneoplastic syndromes in small cell lung cancer. Journal of Thoracic Disease, 2020, 12, 6253-6263.	1.4	34
9	Decreasing incidence of upper age restriction enrollment criteria among cancer clinical trials. Journal of Geriatric Oncology, 2020, 11, 451-454.	1.0	28
10	Intraventricular Cavernomas of the Third Ventricle: Report of 2 Cases and a Systematic Review of the Literature. World Neurosurgery, 2017, 105, 935-943.e3.	1.3	24
11	Wound healing complications in brain tumor patients on Bevacizumab. Journal of Neuro-Oncology, 2015, 124, 501-506.	2.9	18
12	Exclusion of patients with brain metastases from cancer clinical trials. Neuro-Oncology, 2020, 22, 577-579.	1.2	18
13	Radiographic patterns of progression with associated outcomes after bevacizumab therapy in glioblastoma patients. Journal of Neuro-Oncology, 2017, 135, 75-81.	2.9	14
14	Gastrointestinal stromal tumor with intracranial metastasis: case presentation and systematic review of literature. BMC Cancer, 2019, 19, 1119.	2.6	13
15	Highlighting the need for reliable clinical trials in glioblastoma. Expert Review of Anticancer Therapy, 2018, 18, 1031-1040.	2.4	12
16	Treatment strategies for glioblastoma in older patients: age is just a number. Journal of Neuro-Oncology, 2019, 145, 357-364.	2.9	12
17	Effect of health disparities on overall survival of patients with glioblastoma. Journal of Neuro-Oncology, 2019, 142, 365-374.	2.9	9
18	Racial and Socioeconomic Disparities in Patients With Meningioma: A Retrospective Cohort Study. Neurosurgery, 2022, 90, 114-123.	1.1	8

#	Article	IF	CITATIONS
19	Recurrent Papillary Glioneuronal Tumor. World Neurosurgery, 2019, 128, 127-130.	1.3	7
20	Pineal parenchymal tumor of intermediate differentiation: a single-institution experience. Neuro-Oncology Practice, 2020, 7, 613-619.	1.6	7
21	Disparities along the glioblastoma clinical trials landscape. Neuro-Oncology, 2019, 21, 285-286.	1.2	6
22	Intracranial Solitary Fibrous Tumor of the Skull Base: 2 Cases and Systematic Review of the Literature. World Neurosurgery, 2021, 149, e345-e359.	1.3	6
23	Intracranial Erdheim-Chester Disease Mimicking Parafalcine Meningioma: Report of Two Cases and Review of the Literature. World Neurosurgery, 2018, 110, 365-370.	1.3	5
24	Hyperostosis frontalis interna diagnosed after a provoked seizure. BMJ Case Reports, 2020, 13, e236520.	0.5	5
25	The concurrence of multiple sclerosis and glioblastoma. Multiple Sclerosis and Related Disorders, 2021, 50, 102877.	2.0	5
26	Newly diagnosed ganglioglioma in an adult patient with multiple sclerosis. Journal of the Neurological Sciences, 2016, 369, 51-52.	0.6	4
27	IDH mutation status and the development of venous thromboembolism in astrocytoma patients. Journal of the Neurological Sciences, 2021, 427, 117538.	0.6	4
28	Intracranial epithelioid hemangioendothelioma causing subacute loss of vision. Neurology, 2015, 85, 735-736.	1.1	3
29	Delayed imaging abnormalities of neuro-invasive West Nile virus in cancer patients. Journal of the Neurological Sciences, 2015, 350, 115-117.	0.6	3
30	Tyrosine Kinase Inhibitors as a Treatment of Symptomatic CNS Metastases in Oncogene-Driven NSCLC. Journal of Oncology, 2020, 2020, 1-8.	1.3	3
31	Newly Diagnosed Optic Pathway Glioma During Pregnancy. World Neurosurgery, 2019, 127, 58-62.	1.3	2
32	Could patients benefit from whole-brain radiotherapy with unilateral hippocampus sparing?. Reports of Practical Oncology and Radiotherapy, 2021, 26, 454-456.	0.6	2
33	QOLP-30. CLINICAL PREDICTIVE MODEL FOR THE DEVELOPMENT OF VENOUS THROMBOEMBOLISM IN GLIOBLASTOMA. Neuro-Oncology, 2019, 21, vi204-vi204.	1.2	1
34	HOUT-18. TREATMENT STRATEGIES FOR GLIOBLASTOMA IN OLDER PATIENTS: AGE IS JUST A NUMBER. Neuro-Oncology, 2019, 21, vi115-vi116.	1.2	1
35	Multicentric non-enhancing lesions in glioblastoma: A retrospective study. Journal of Clinical Neuroscience, 2021, 85, 20-26.	1.5	1
36	Practical guidance for telemedicine use in neuro-oncology. Neuro-Oncology Practice, 2022, 9, 91-104.	1.6	1

#	Article	IF	CITATIONS
37	Hemorrhagic cavum vergae colloid cyst: A presentation of anterograde amnesia without hydrocephalus., 2022, 13, 148.		1
38	Spinal Dural Arteriovenous Fistula and Concomitant Intramedullary Spinal Lesion. Canadian Journal of Neurological Sciences, 2018, 45, 238-239.	0.5	0
39	ATIM-07. WINDOW-OF-OPPORTUNITY CLINICAL TRIAL OF PEMBROLIZUMAB IN RECURRENT GLIOBLASTOMA PATIENTS. Neuro-Oncology, 2018, 20, vi2-vi2.	1.2	0
40	EPID-08. EFFECT OF HEALTH DISPARITIES ON OVERALL SURVIVAL OF PATIENTS WITH GLIOBLASTOMA. Neuro-Oncology, 2018, 20, vi81-vi81.	1.2	0
41	Spinal meningioma in a patient with multiple sclerosis. , 2020, 11, 196.		O
42	INNV-27. AN INNOVATIVE VIRTUAL MULTI-INSTITUTIONAL, MULTIDISCIPLINARY NEURO-ONCOLOGY TUMOR BOARD: THE NIH-NOB EXPERIENCE DURING THE COVID-19 PANDEMIC. Neuro-Oncology, 2021, 23, vi111-vi111.	1.2	0
43	BIOM-01. TYROSINE KINASE INHIBITORS AS A TREATMENT OF SYMPTOMATIC CNS METASTASES IN ONCOGENE-DRIVEN NSCLC. Neuro-Oncology, 2020, 22, ii1-ii1.	1.2	O
44	NCMP-10. IDH MUTATION STATUS AND THE DEVELOPMENT OF VENOUS THROMBOEMBOLISM IN ASTROCYTOMA PATIENTS. Neuro-Oncology, 2020, 22, ii125-ii125.	1.2	0